Advertisement

Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in Cancer

  • Joan M. CarboniEmail author
  • Mark Wittman
  • Fei Huang
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The insulin-like growth factor receptor 1 (IGF-1R) signaling pathway has emerged as an important target for cancer therapy. A variety of selective tyrosine kinase inhibitor (TKI) molecules have been described which show that attenuation of this pathway is associated with inhibition of tumor growth, and enhanced sensitivity to therapeutic agents, including cytotoxic and other molecular targeted agents. The majority of data available on the treatment effects of TKIs are those established preclinically. Clinical data are just beginning to emerge, but it is still too early to determine the impact that these therapies may have in the oncology armamentarium. In this chapter, preclinical and clinical data are described for IGF-1R TKIs. Where available, resistance data are introduced, as this is a mounting issue for other TKIs used in cancer treatment.

Keywords

Multiple Myeloma Insulin Receptor Sarcoma Cell Line SCLC Cell Line Ewing Sarcoma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Andrews DW, et al. (2001). J Clin Oncol 19(8): 2189–200.Google Scholar
  2. Arteaga CL and Osborne CK (1989). Cancer Res 49(22): 6237–41.Google Scholar
  3. Beech DJ, et al. (2001). Oncol Rep 8(2): 325–9.Google Scholar
  4. Belfiore A (2007). Curr Pharm Des 13(7): 671–86.Google Scholar
  5. Byron SA, et al. (2006). Br J Cancer 95(9): 1220–8.Google Scholar
  6. Camirand A, et al. (2005). Breast Cancer Res 7(4): R570–9.Google Scholar
  7. Campbell RA, et al. (2001). J Biol Chem 276(13): 9817–24.Google Scholar
  8. Cao L, et al. (2008). Cancer Res 68(19): 8039–48.Google Scholar
  9. Carboni JM, et al. (2005). Cancer Res 65(9): 3781–7.Google Scholar
  10. Carboni JM, et al. (2009). Mol Cancer Ther 8(12): 3341–9.Google Scholar
  11. Carden CP, et al. (2009a). Clin Pharmacol Ther 85(2): 131–3.Google Scholar
  12. Carden CP, et al. (2009b). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 3544.Google Scholar
  13. Casa AJ, et al. (2008). Frontiers in Bioscience 13: 3273–87.Google Scholar
  14. Chakraborty AK, et al. (2008). Cancer Res 68(5): 1538–45.Google Scholar
  15. Chan JM, et al. (1998). Science 279(5350): 563–6.Google Scholar
  16. Chu KC, et al. (2001). Cancer 92(1): 37–45.Google Scholar
  17. Clemens PL, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract A101.Google Scholar
  18. Cortes J, et al. (2008). ASH Annual Meeting Abstracts 112(11): Abstract 3232.Google Scholar
  19. Cosaceanu D, et al. (2007). Oncogene 26(17): 2423–34.Google Scholar
  20. Cunningham MP, et al. (2006). Int J Oncol 28(2): 329–35.Google Scholar
  21. D’Ambrosio C, et al. (1996). Cancer Res 56(17): 4013–20.Google Scholar
  22. D’cunja J, et al. (2007). Eur J Cancer 43(10): 1581–9.Google Scholar
  23. Desai J, et al. (2010). J Clin Oncol (Meeting Abstracts) 28(7S): Abstract 3104.Google Scholar
  24. Desbois-Mouthon C, et al. (2009). Clin Cancer Res 15(17): 5445–56.Google Scholar
  25. Dinchuk JE, et al. (2010). Endocrinology: manuscript submitted.Google Scholar
  26. Dunn SE, et al. (1997). Cancer Res 57(13): 2687–93.Google Scholar
  27. Engelman JA, et al. (2005). Proc Natl Acad Sci USA. 102(10): 3788–93.Google Scholar
  28. Frasca F, et al. (1999). Mol Cell Biol 19(5): 3278–88.Google Scholar
  29. Garcia-Echeverria C, et al. (2004). Cancer Cell 5(3): 231–9.Google Scholar
  30. Girnita A, et al. (2004). Cancer Res 64(1): 236–42.Google Scholar
  31. Gong Y, et al. (2009). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 8095.Google Scholar
  32. Gooch JL, et al. (1999). Breast Cancer Res Treat 56(1): 1–10.Google Scholar
  33. Gualberto A and Pollak M (2009). Oncogene 28(34): 3009–21.Google Scholar
  34. Haluska P, et al. (2006). Cancer Res 66(1): 362–71.Google Scholar
  35. Haluska P, et al. (2007). Proceedings from the 15th SPORE Investigators’ Workshop.Google Scholar
  36. Haluska P, et al. (2008). Mol Cancer Ther 7(9): 2589–98.Google Scholar
  37. Haluska P, et al. (2009). 32nd San Antonio Breast Cancer Symposium.Google Scholar
  38. Harmenberg J, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract B256.Google Scholar
  39. Harris LN, et al. (2007). Clin Cancer Res. 13(4): 1198–207.Google Scholar
  40. Harzstark AL, et al. (2007). J Clin Oncol 25(18S).Google Scholar
  41. Hendrickson AW and Haluska P (2009). Curr Opin Investig Drugs 10(10): 1032–40.Google Scholar
  42. Hewish M, et al. (2009). Recent Pat Anticancer Drug Discov 4(1): 54–72.Google Scholar
  43. Hillerman SM, et al. (2010). Proceedings of the 101st Annual Meeting of the AACR; Abstract 363.Google Scholar
  44. Huang F, et al. (2009). Cancer Res 69(1): 161–70.Google Scholar
  45. Huang F, et al. (2010). Cancer Res 70(18): 7221–31.Google Scholar
  46. Hubbard RD and Wilsbacher JL (2007). ChemMedChem 2(1): 41–6.Google Scholar
  47. Ji QS, et al. (2007). Mol Cancer Ther 6(8): 2158–67.Google Scholar
  48. Jones HE, et al. (2004). Endocr Relat Cancer 11(4): 793–814.Google Scholar
  49. Jones HE, et al. (2006). Br J Cancer 95(2): 172–80.Google Scholar
  50. Kalli KR, et al. (2002). Endocrinology 143(9): 3259–67.Google Scholar
  51. Karp DD, et al. (2009). J Clin Oncol 27(15): 2516–22.Google Scholar
  52. Kim HJ, et al. (2007). Mol Cell Biol 27(8): 3165–75.Google Scholar
  53. Knowlden JM, et al. (2005). Endocrinology 146(11): 4609–18.Google Scholar
  54. Kobayashi S, et al. (2005). N Engl J Med. 352(8): 786–92.Google Scholar
  55. Kostler WJ, et al. (2006). J Cancer Res Clin Oncol 132(1): 9–18.Google Scholar
  56. Lee AV, et al. (1997). J Endocrinol 152(1): 39–47.Google Scholar
  57. Lee J, et al. (2007). Mol Pharmacol. 72(4): 1082–93.Google Scholar
  58. LeRoith D, et al. (1995). Ann Intern Med 122(1): 54–9.Google Scholar
  59. Li R, et al. (2009). J Med Chem 52(16): 4981–5004.Google Scholar
  60. Lindsay CR, et al. (2009). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 2559.Google Scholar
  61. Litzenburger BC, et al. (2009). 32nd San Antonio Breast Cancer Symposium.Google Scholar
  62. Long L, et al. (1995). Cancer Res 55(5): 1006–9.Google Scholar
  63. Lu Y, et al. (2001). J Natl Cancer Inst 93(24): 1852–7.Google Scholar
  64. Macaulay VM, et al. (2001). Oncogene 20(30): 4029–40.Google Scholar
  65. Maiso P, et al. (2008). Br J Haematol 141(4): 470–82.Google Scholar
  66. Martins AS, et al. (2008). Cancer Res 68(15): 6260–70.Google Scholar
  67. Min Y, et al. (2005). Gut 54(5): 591–600.Google Scholar
  68. Mitsiades CS, et al. (2004). Cancer Cell 5(3): 221–30.Google Scholar
  69. Moller DE, et al. (1989). Mol Endocrinol 3(8): 1263–9.Google Scholar
  70. Morgillo F, et al. (2006). Cancer Res 66(20): 10100–11.Google Scholar
  71. Morgillo F, et al. (2007). Clin Cancer Res 13(9): 2795–803.Google Scholar
  72. Mukohara T, et al. (2009). Cancer Lett 282(1): 14–24.Google Scholar
  73. Mulvihill M, et al. (2008). Proceedings of the 101st Annual Meeting of the AACR; Abstract 4893.Google Scholar
  74. Nahta R, et al. (2005). Cancer Res 65(23): 11118–28.Google Scholar
  75. Nahta R, et al. (2007). Mol Cancer Ther 6(2): 667–4.Google Scholar
  76. Nakamura S, et al. (1997). Exp Cell Res. 235(1): 287–94.Google Scholar
  77. Pandini G, et al. (1999). Clin Cancer Res 5(7): 1935–44.Google Scholar
  78. Pandini G, et al. (2002). J Biol Chem 277(42): 39684–95.Google Scholar
  79. Pao W, et al. (2005). PLoS Med. 2(3): e73.Google Scholar
  80. Perer ES, et al. (2000). J Surg Res 94(1): 1–5.Google Scholar
  81. Peretz S, et al. (2001). Proc Natl Acad Sci U S A. 98(4): 1676–81.Google Scholar
  82. Peruzzi F, et al. (1999). Mol Cell Biol 19(10): 7203–15.Google Scholar
  83. Pietrzkowski Z, et al. (1993). Cancer Res 53(5): 1102–6.Google Scholar
  84. Pitts TM, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract A39.Google Scholar
  85. Pollak M (2008). Curr Opin Pharmacol 8(4): 384–92.Google Scholar
  86. Sciacca L, et al. (1999). Oncogene 18(15): 2471–9.Google Scholar
  87. Sciacca L, et al. (2002). Oncogene 21(54): 8240–50.Google Scholar
  88. Scotlandi K, et al. (2005). Cancer Res 65(9): 3868–76.Google Scholar
  89. Smith DC, et al. (2010). J Clin Oncol (Meeting Abstracts) 28(7S): Abstract 3105.Google Scholar
  90. Tan AC, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract C22.Google Scholar
  91. Turner BC, et al. (1997). Cancer Res 57(15): 3079–83.Google Scholar
  92. Ulanet DB, et al. (2010). Proc Natl Acad Sci USA.Google Scholar
  93. Valentinis B and Baserga R (2001). Mol Pathol 54(3): 133–7.Google Scholar
  94. van der Veeken J, et al. (2009). Curr Cancer Drug Targets 9(6): 748–60.Google Scholar
  95. Velaparthi U, et al. (2008). J Med Chem 51(19): 5897–900.Google Scholar
  96. Vella V, et al. (2002). J Clin Endocrinol Metab 87(1): 245–54.Google Scholar
  97. Warshamana-Greene GS, et al. (2004). Mol Cancer Ther 3(5): 527–35.Google Scholar
  98. Warshamana-Greene GS, et al. (2005). Clin Cancer Res 11(4): 1563–71.Google Scholar
  99. Wen B, et al. (2001). Br J Cancer 85(12): 2017–21.Google Scholar
  100. Weroha SJ and Haluska P (2008). J Mammary Gland Biol Neoplasia 13(4): 471–83.Google Scholar
  101. Wittman MD, et al. (2009a). J Med Chem 52(23): 7360–3.Google Scholar
  102. Wittman MD, et al. (2009b). Annual Reports in Medicinal Chemistry 44: 281–299.Google Scholar
  103. Zha J, et al. (2009). Mol Cancer Ther 8(8): 2110–21.Google Scholar
  104. Zhang H, et al. (2007). J Clin Invest. 117(8): 2051–8.Google Scholar
  105. Zhang H, et al. (2010). Oncogene in press.Google Scholar
  106. Zhou DJ, et al. (1990). Cancer Res 50(21): 6949–54.Google Scholar
  107. Zimmermann K, et al. (2008). Bioorg Med Chem Lett 18(14): 4075–80.Google Scholar
  108. Zimmermann K, et al. (2010). Bioorg Med Chem Lett 20(5): 1744–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Oncology Drug DiscoveryBristol Myers Squibb CompanyPrincetonUSA
  2. 2.Oncology ChemistryWallingfordUSA
  3. 3.Clinical Biomarkers-Oncology/DMCPPrincetonUSA

Personalised recommendations